Open AccessClinical efficacy of tocilizumab treatment in severe and critical COVID-19 patients
Author(s) -
Jia Zeng,
Minghui Xie,
Jing Yang,
Sheng-Wu Chao,
Er-li Xu
Publication year - 2020
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v8.i17.3763
Subject(s) - tocilizumab , medicine , cytokine storm , pneumonia , interleukin 6 , fibrinogen , cytokine release syndrome , atypical pneumonia , gastroenterology , cytokine , covid-19 , disease , infectious disease (medical specialty)
The main pathophysiological basis of coronavirus disease 2019 (COVID-19) causing respiratory failure is a cytokine storm and interleukin-6 (IL-6) is an important component of the COVID-19 cytokine storm. As a specific antagonist of IL-6, tocilizumab may block the cytokine storm of COVID-19. The Diagnosis and Treatment Guidelines of New Coronavirus Pneumonia (7 th Edition) includes tocilizumab as a recommended drug for immunotherapy in severe and critical COVID-19 patients. However, the specific clinical efficacy of tocilizumab in the treatment of COVID-19 patients is worth studying.